Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3243 - Met/Axl system as a dual target in the mesothelioma pathway and invasiveness

Date

11 Sep 2017

Session

Poster display session

Presenters

Giuseppe Viscardi

Citation

Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390

Authors

G. Viscardi, V. Ciaramella, C.M. Della Corte, F. Papaccio, G. Esposito, R. Di Liello, T. Troiani, M. Orditura, F. Ciardiello, F. Morgillo

Author affiliations

  • Medical Oncology, Department Of Clinical And Experimental Medicine "f. Magrassi", University of Campania "Luigi Vanvitelli", 80131 - Naples/IT
More

Resources

Abstract 3243

Background

Malignant pleural mesothelioma is an aggressive and highly lethal disease. Conventional chemotherapies and radiation therapy have limited efficacy. Many evidences suggest the roles of receptors tyrosine kinase (RTKs) in mesothelioma pathogenesis, in particular epidermal growth factor (EGFR), Met and Axl. Axl activation is involved in proliferation and inhibition of apoptosis, and its over-expression represents a key molecular determinant underlying the development of acquired resistance to targeted anticancer agents.

Methods

Different histological types, epithelioid, sarcomatoid and mixed, of human mesothelioma cell lines were used. Protein levels of Met, Axl and its ligand, growth arrest-specific 6 (Gas6) were evaluated by Western Blot analysis. We conducted in vitro treatments with different doses of Foretinib, dual inhibitor of Met and Axl, in order to demonstrated the variation of cell proliferation and migration through MTT and Colony Forming Assay at the range dose 0.5-1 µM of Foretinib. Lastly, the rate of cell apoptosis was quantified by flow cytometry.

Results

The presence of Met, Axl and Gas6 proteins were found in all cell lines analyzed with different expression pattern. The dose escalation of Foretinib from 0.01 µM to 2 µM strongly inhibited cell proliferation and migration of mesothelioma cell lines. Treatment with Foretinib (at the dose 0.5 µM and 1 µM), determining a significantly increase of apoptosis rate (up to 50%) in specific histological type suggesting a different cell sensibility.

Conclusions

The co-activation of MET and AXL in mesothelioma cell lines suggests that these kinases could serve as novel therapeutic targets. MET and AXL inhibitors could be used as novel anticancer therapies influence clinically meaningful end points including metastatic recurrence and survival in the majority of tumour types.

Clinical trial identification

Legal entity responsible for the study

University of Campania “Luigi Vanvitelli”

Funding

Associazione Italiana per la Ricerca sul Cancro (AIRC)

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.